查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012697

自体免疫疾病治疗市场：2026-2032年全球市场预测（依药物类别、作用机制、给药途径、适应症、最终用户及通路划分）

Autoimmune Disease Drugs Market by Drug Class, Mechanism Of Action, Route Of Administration, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，自体免疫疾病治疗市场价值将达到 1,258.6 亿美元，到 2026 年将成长至 1,356.4 亿美元，到 2032 年将达到 2,221.9 亿美元，年复合成长率为 8.45%。

主要市场统计数据
基准年 2025 1258.6亿美元
预计年份：2026年 1356.4亿美元
预测年份 2032 2221.9亿美元
复合年增长率 (%) 8.45%

概述了临床创新、商业性复杂性和政策因素如何共同重新定义自体免疫疾病的治疗策略。

本执行摘要概述了目前重塑自体免疫疾病治疗格局的临床、商业性和政策趋势。内容涵盖了治疗方法的进展、作用机制的演变、给药途径的改变以及分销和医疗服务模式的转变。本文重点阐述了科学创新如何与报销压力、供应链脆弱性以及患者对以患者为中心的医疗服务日益增长的期望相互交织，从而形成一个需要灵活应对的复杂环境。

科学突破、支付方压力和以患者为中心的医疗保健服务模式如何相互作用，重新定义自体免疫疾病治疗领域的竞争格局和临床动态。

自体免疫治疗领域正经历一系列变革，其驱动力来自科学进步、监管法规的演变以及患者和支付方期望的转变。治疗方法不再只是渐进式的改进，而是涵盖了新型生物製药、选择性日益增强的细胞激素抑制剂以及挑战传统肠外给药优势的口服标靶治疗。这些进展正在加速针对B细胞耗竭和多种白细胞白细胞介素通路等机制的标靶开发项目，而JAK抑制剂选择性的提高也促使人们重新评估其风险获益比及其在治疗流程中的地位。

评估到 2025 年关税制度变化对供应链韧性、製造在地化和商业性准入策略的综合影响。

贸易和关税体系的政策变化可能对全球医药供应链的经济和物流产生重大影响，预计到2025年，累积效应正迫使产业相关人员重新评估其采购、生产和定价策略。某些原材料和成品关税的提高加剧了依赖跨境分销活性药物成分、生物製药组分和特种包装材料的製造商的成本压力。对于需要复杂低温运输物流和多成分供应链网络的治疗方法，这些压力尤其严峻。

综合細項分析揭示了药物类别、作用机制、给药途径、适应症、分销和最终用户方面的差异如何影响策略和营运挑战。

市场区隔为评估临床差异化和商业性机会的契合点提供了一个切实可行的观点。依药物类别划分，市场包括生物製药、生物相似药和小分子药物，其中生物製药可细分为融合蛋白、单株抗体和胜肽类药物。这些区分对于生产复杂性、监管路径和生命週期管理策略至关重要。依作用机制，疗法可分为B细胞清除剂、白细胞介素抑制剂、JAK抑制剂和TNF抑制剂，其中白细胞介素抑制剂又可细分为IL-17、IL-23和IL-6抑制剂，JAK抑制剂又可细分为JAK-1、JAK-1/2和JAK-3抑制剂。这种作用机制的细分有助于标靶选择、安全性监测以及在特定适应症中建立竞争优势。

美洲、欧洲、中东和非洲以及亚太地区的监管环境、支付方和生产环境有何不同？这些差异又如何影响各地区的市场进入与上市策略？

区域趋势以不同的方式影响研发重点、监管路径、支付方行为和打入市场策略。在美洲，定价和报销讨论深受支付方主导的处方药清单管理以及日益重视基于价值的合同的影响，而商业性成功往往取决于健全的患者支持计划和与专科药房的合作。在欧洲、中东和非洲市场，法律规范和定价压力呈现复杂多元的格局。集中化的监管路径和联合采购机制与各国不同的报销标准并存，这为战略定价和适应性上市顺序创造了机会，并儘可能利用区域监管协调。亚太市场的特点是监管环境快速变化、本地产能不断扩大以及支付方环境多元化。打入市场策略通常强调成本效益高的生产、与本地契约製造的合作以及反映当地医疗服务模式的客製化准入计划。

强调科学差异化、卓越製造和以支付方为导向的证据产生的竞争需求正在塑造整个治疗领域的企业策略。

自体免疫疗法领域的竞争格局由大型生物製药公司、专业生物技术创新企业、契约製造组织 (CMO) 以及新兴生物相似参与企业组成。主要企业正投资于下一代生物製药、精准靶向小分子药物以及将治疗与数位化用药依从性支持和监测解决方案相结合的方案。策略联盟、授权协议和定向推广授权仍然是加速产品线多元化和获取新型作用机制的常用策略，而无需承担新药研发的全部成本。

领导者可采取切实可行的策略步骤，加强价值链、证据产生和差异化价值提案，以加速招募并确保永续取得。

产业领导企业应优先考虑一系列切实可行的倡议，将科学进步转化为永续的商业性价值。首先，透过多元化采购、扩大区域製造能力以及製定灵活的供应商协议来增强价值链韧性，从而降低关税和物流中断带来的风险。其次，透过将真实世界结果和卫生经济学终点纳入临床试验，使临床开发与支付方的证据需求保持一致，从而促进报销谈判并创造基于价值的合约机会。

透明地整合同侪审查研究、监管分析、临床专家访谈和产品线概述，以支持强有力的策略建议。

本执行摘要所依据的研究整合了多种证据来源，旨在提供可操作的策略洞察。研究人员对同行评审文献、监管指导文件和公开的临床试验註册资讯进行了二次证据审查，以梳理治疗方法进展和安全性概况。此外，研究人员还与临床医生、卫生经济学家、支付方和供应链专家进行了有针对性的专家访谈，以定性检验观察到的趋势并阐明其对营运的影响。最后，研究人员利用研发管线分析和作用机制映射，使研发方向与未满足的需求和竞争定位一致。

这些结论结合了治疗方法创新、营运韧性和与支付方的合作，为实现可持续的医疗服务取得和商业性成功制定了连贯的蓝图。

自体免疫疾病治疗市场正处于一个转折点，科学进步、支付方审查和不断演变的医疗模式相互交织，既带来了风险，也带来了机会。生物製药、生物相似药和标靶小分子药物等领域的治疗创新正在拓展治疗选择，并实现更个人化的治疗，但这些进步也带来了日益复杂的营运和商业挑战。能够将临床差异化优势与强大的生产能力、积极的支付方互动以及以患者为中心的医疗服务模式相结合的製造商，将最有可能获得长期价值。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：自体免疫疾病治疗市场：依药物类别划分

  • 生物製药
    • 融合蛋白
    • 单株抗体
    • 胜肽
  • 生物相似药
  • 低分子化合物

第九章：自体免疫疾病治疗药物市场（依作用机转划分）

  • B细胞清除剂
  • IL抑制剂
    • IL-17抑制剂
    • IL-23抑制剂
    • IL-6抑制剂
  • JAK抑制剂
    • JAK1抑制剂
    • JAK1/2抑制剂
    • JAK3抑制剂
  • TNF抑制剂

第十章：自体免疫疾病治疗市场：依给药途径划分

  • 口服
    • 胶囊
    • 解决方案
    • 药片
  • 肠外
    • 静脉
    • 皮下

第十一章：自体免疫疾病治疗市场：依适应症划分

  • 发炎性肠道疾病
    • 克隆氏症
    • 溃疡性大肠炎
  • 狼疮
  • 多发性硬化症
  • 银屑病
    • 斑块型干癣
    • 干癣性关节炎
  • 类风湿性关节炎

第十二章：自体免疫疾病治疗市场：依最终用户划分

  • 诊所
  • 居家医疗
  • 医院

第十三章：自体免疫疾病治疗市场：依通路划分

  • 离线
  • 在线的

第十四章：自体免疫疾病治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：自体免疫疾病治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：自体免疫疾病治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国自体免疫疾病治疗市场

第十八章：中国自体免疫疾病治疗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Mallinckrodt plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-436901065FE5

The Autoimmune Disease Drugs Market was valued at USD 125.86 billion in 2025 and is projected to grow to USD 135.64 billion in 2026, with a CAGR of 8.45%, reaching USD 222.19 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 125.86 billion
Estimated Year [2026] USD 135.64 billion
Forecast Year [2032] USD 222.19 billion
CAGR (%) 8.45%

High-level orientation to clinical innovation, commercial complexity, and policy drivers that are jointly redefining autoimmune disease treatment strategies

This executive summary synthesizes current clinical, commercial, and policy developments that are reshaping the autoimmune therapeutics landscape. It synthesizes recent advances in therapeutic modalities, evolving mechanisms of action, shifts in routes of administration, and changing distribution and care-delivery models. The narrative highlights where scientific innovation intersects with reimbursement pressures, supply chain fragility, and heightened expectations for patient-centered care, producing a complex environment that demands agile strategic responses.

The introduction frames the competitive arena in terms of therapeutic differentiation and operational complexity. Biologic therapies have redefined standards of care across multiple indications, while biosimilars are increasing options for payers and providers. Simultaneously, oral small molecules and targeted inhibitors are altering patient preferences and adherence patterns. These dynamics unfold against a backdrop of intensified regulatory scrutiny, greater emphasis on real-world evidence, and payer initiatives designed to link outcomes to payment. The result is a market that rewards innovation in therapeutic efficacy and delivery, as well as excellence in commercialization, access strategy, and stakeholder engagement.

This section prepares the reader to evaluate subsequent analyses on technological shifts, policy impacts, segmentation insights, and regional differences. It prioritizes an integrated view that balances clinical promise with pragmatic considerations for manufacturing, distribution, and market access.

How scientific breakthroughs, payer pressures, and patient-centered delivery models are converging to redefine competitive and clinical dynamics in autoimmune therapeutics

The autoimmune therapeutics landscape is experiencing a series of transformative shifts driven by scientific advances, regulatory evolution, and changing patient and payer expectations. Therapeutic innovation is no longer limited to incremental improvements; it now includes novel biologic constructs, increasingly selective cytokine inhibitors, and oral targeted therapies that challenge traditional parenteral dominance. These advances have accelerated targeted development programs against mechanisms such as B cell depletion and multiple interleukin pathways, while the refinement of JAK inhibitor selectivity is prompting a reappraisal of benefit-risk trade-offs and positioning in treatment algorithms.

Concurrently, the maturation of biosimilar frameworks in several regulatory jurisdictions is altering competitive dynamics and accelerating cost-containment strategies among payers and health systems. This has prompted originator manufacturers to pursue differentiated value propositions, including novel formulations, extended-release technologies, and bundled service offerings that incorporate patient support and adherence tools. The shift toward patient-centric care models has also elevated the importance of route of administration; oral therapies are gaining traction for convenience and adherence potential, while subcutaneous self-administration and homecare-enabled intravenous services redefine where chronic treatment occurs.

Technological enablers such as remote monitoring, digital adherence platforms, and integrated data streams are enhancing real-world evidence generation and supporting outcomes-based contracting. Taken together, these shifts are remapping the competitive field, creating new entry points for novel modalities, and demanding cross-functional coordination between R&D, regulatory affairs, commercial strategy, and supply chain operations.

Assessing the compound effects of evolving tariff regimes on supply chain resilience, manufacturing localization, and commercial access strategies through 2025

Policy changes in trade and tariff regimes can materially affect the economics and logistics of global pharmaceutical supply chains, and the cumulative effects projected through 2025 have prompted industry participants to reassess sourcing, manufacturing, and pricing strategies. Increased tariff exposure on certain inputs and finished goods amplifies cost pressures for manufacturers that rely on cross-border flows for active pharmaceutical ingredients, biologics components, and specialized packaging. These pressures are particularly acute for therapies that require complex cold-chain logistics and multi-component supply networks.

In response, manufacturers are diversifying sourcing footprints, accelerating regional manufacturing investments, and negotiating more flexible supplier terms to insulate production from tariff volatility. Payers and health systems may respond to higher procurement costs by intensifying formulary management and prioritizing cost-effective alternatives, which could accelerate uptake of lower-cost biosimilars and incentivize negotiations around value-based agreements. At the same time, manufacturers are increasingly examining total cost of care narratives that encompass not just acquisition price but also patient outcomes, adherence benefits, and reductions in healthcare utilization, which can mitigate tariff-driven margin compression.

Logistically, tariffs contribute to longer lead times and higher inventory carrying costs as companies build buffer stocks to manage tariff-related interruptions. Regulatory and customs complexity can further slow product movement and complicate multi-jurisdictional clinical supply operations. Overall, the cumulative tariff environment through 2025 encourages strategies that prioritize supply chain resilience, closer collaboration with contract manufacturers and logistics partners, and proactive engagement with payers to preserve access while managing affordability concerns.

Integrated segmentation analysis revealing how drug class, mechanism, route, indication, distribution, and end-user distinctions drive strategic and operational imperatives

Segmentation provides a practical lens to evaluate where clinical differentiation and commercial opportunity align. Based on drug class, the market comprises biologics, biosimilars, and small molecules, with biologics further divided into fusion proteins, monoclonal antibodies, and peptides; these distinctions matter for manufacturing complexity, regulatory pathways, and lifecycle management strategies. Based on mechanism of action, treatments are clustered across B cell depleting agents, interleukin inhibitors, JAK inhibitors, and TNF inhibitors, with interleukin inhibitors further parsed into IL17, IL23, and IL6 inhibitors and JAK inhibitors categorized into JAK1, JAK1/2, and JAK3 inhibitors; this mechanistic granularity informs target selection, safety monitoring, and competitive positioning within specific indications.

Route of administration segmentation tracks oral and parenteral options, where oral forms include capsules, solutions, and tablets and parenteral forms encompass intravenous and subcutaneous delivery; route differences affect patient preference, adherence, clinic burden, and homecare feasibility. Indication-based segmentation addresses inflammatory bowel disease, lupus, multiple sclerosis, psoriasis, and rheumatoid arthritis, noting that inflammatory bowel disease is further detailed into Crohn's disease and ulcerative colitis, while psoriasis includes plaque psoriasis and psoriatic arthritis; indication-level nuances dictate trial design, endpoints, and payer evidence requirements. Distribution channel segmentation distinguishes offline and online pathways, which impacts patient access models, specialty pharmacy engagement, and digital support services. Finally, end user segmentation covers clinics, homecare settings, and hospitals, and these care settings determine administration logistics, reimbursement codes, and provider training needs.

Interpreting these segmentation dimensions in combination highlights where clinical innovation can yield differentiated commercial returns and where operational investments will be necessary to translate therapeutic advances into accessible care. For example, a monoclonal antibody targeting an IL23 pathway intended for subcutaneous administration will have different commercialization imperatives than an oral JAK1 inhibitor, including distinct manufacturing priorities, patient support ecosystems, and distribution partnerships.

How divergent regulatory, payer, and manufacturing landscapes across the Americas, Europe Middle East & Africa, and Asia-Pacific demand tailored market access and launch strategies

Regional dynamics shape R&D priorities, regulatory pathways, payer behavior, and access strategies in distinct ways. In the Americas, pricing and reimbursement debates are heavily influenced by payer-driven formulary management and an increasing focus on value-based arrangements, while commercial success often hinges on robust patient support programs and specialty pharmacy integration. European, Middle Eastern, and African markets present a mosaic of regulatory frameworks and pricing pressures; centralized regulatory pathways and joint procurement mechanisms coexist with diverse national reimbursement criteria, creating opportunities for strategic pricing and adaptive launch sequencing that leverage regional regulatory harmonization where possible. Asia-Pacific markets are notable for rapidly evolving regulatory frameworks, growing local manufacturing capacity, and heterogeneous payer landscapes; market entry strategies commonly emphasize cost-efficient manufacturing, partnerships with regional contract manufacturers, and tailored access programs that reflect local healthcare delivery models.

Each regional cluster demands differentiated approaches to clinical development, regulatory engagement, and commercialization. The Americas may prioritize evidence packages that support outcomes-based contracting and demonstrate real-world impact on healthcare utilization, whereas the Europe, Middle East & Africa region often requires nuanced pricing strategies and engagement with multiple national agencies. Asia-Pacific strategies frequently balance accelerated regulatory approvals with scalable manufacturing and distribution partnerships to meet diverse access and affordability constraints. Recognizing these regional distinctions early in product planning enables optimized trial site selection, manufacturing footprint decisions, and launch sequencing that align with both clinical and commercial objectives.

Competitive imperatives emphasizing scientific differentiation, manufacturing excellence, and payer-aligned evidence generation that shape corporate strategies across the therapeutic landscape

Competitive dynamics across the autoimmune therapeutics space are characterized by a mix of large biopharma incumbents, specialized biotech innovators, contract manufacturing organizations, and emerging biosimilar entrants. Leading companies are investing in next-generation biologics, precision-targeted small molecules, and combination approaches that pair therapeutic agents with digital adherence or monitoring solutions. Strategic collaborations, licensing agreements, and targeted in-licensing remain common tactics to accelerate pipeline diversification and to access novel mechanisms without incurring the full costs of de novo discovery.

Manufacturing and supply chain capabilities are increasingly central competitive differentiators, particularly for complex biologics and therapies requiring cold-chain logistics. Firms that can demonstrate localized manufacturing, robust quality systems, and flexible supply architectures are better positioned to mitigate tariff and logistics risks and to support rapid scale-up. On the commercial front, value articulation and payer engagement are evolving into sophisticated, data-driven dialogues; companies that proactively generate and share real-world evidence and patient-reported outcomes are more likely to secure preferred formulary positions and to participate in outcomes-based arrangements.

Smaller companies and startups are leveraging niche differentiation, such as highly selective pathway targeting or novel delivery technologies, to create acquisition or partnership opportunities with larger players. Meanwhile, biosimilar entrants are intensifying price competition in established classes, prompting originator companies to pursue lifecycle strategies that emphasize differentiation through improved formulations, convenience, and integrated services. Overall, the competitive environment rewards integrated strategies that combine scientific differentiation, manufacturing excellence, and payer-centered value demonstration.

Actionable strategic moves for leaders to strengthen supply chains, evidence generation, and differentiated value propositions that accelerate adoption and ensure sustainable access

Industry leaders should prioritize a set of practical actions to convert scientific advances into sustainable commercial value. First, invest in supply chain resilience by diversifying sourcing, expanding regional manufacturing capabilities, and developing flexible supplier agreements that reduce exposure to tariff and logistics shocks. Second, align clinical development with payer evidence needs by embedding real-world outcomes and health-economic endpoints into trials, thereby facilitating reimbursement discussions and enabling value-based contracting opportunities.

Third, pursue differentiated product and service bundles that combine therapeutic efficacy with adherence support, digital monitoring, and patient education to capture a broader measure of value. Fourth, adopt a portfolio approach that balances high-margin biologics with strategically chosen biosimilar or small-molecule opportunities to preserve access in cost-sensitive markets. Fifth, tailor market entry and commercialization strategies by region, prioritizing regulatory pathways, local manufacturing partnerships, and distribution models that reflect the Americas, Europe, Middle East & Africa, and Asia-Pacific nuances.

Leaders should also formalize payer engagement plans early, using iterative evidence generation to refine value propositions and to negotiate innovative contracting models. Finally, invest in cross-functional capabilities-regulatory affairs, health economics, real-world evidence, and digital health integration-to ensure that scientific progress translates into durable clinical uptake and sustainable access across diverse care settings.

Transparent synthesis of peer-reviewed research, regulatory analysis, clinical expert interviews, and pipeline landscaping to support robust strategic recommendations

The research underpinning this executive summary synthesizes multiple evidence streams to deliver actionable strategic insight. Secondary evidence reviews were conducted across peer-reviewed literature, regulatory guidance documents, and publicly available clinical trial registries to map therapeutic advances and safety profiles. Targeted expert interviews with clinicians, health economists, payers, and supply chain specialists provided qualitative validation of observed trends and clarified operational implications. Pipeline landscaping and mechanism-of-action mapping were used to align R&D trajectories with clinical unmet needs and competitive positioning.

Comparative regulatory analysis examined approval pathways, biosimilar frameworks, and pricing mechanisms across major jurisdictions to identify access levers and potential barriers. Case study review of notable launches and market-access arrangements informed best-practice recommendations on payer negotiation and patient support program design. Limitations of the methodology include reliance on available public data where proprietary commercial intelligence was not accessible, and the inherently dynamic nature of clinical development and policy which may evolve after the cut-off for this analysis. Wherever possible, findings were triangulated across multiple sources and reviewed by subject-matter experts to enhance robustness and reduce bias.

The research adheres to principles of transparency and reproducibility: methods, inclusion criteria, and the types of expert inputs are documented, and the analysis emphasizes qualitative synthesis over quantitative projection to ensure practical relevance for decision-makers.

Concluding synthesis that links therapeutic innovation, operational resilience, and payer engagement into a cohesive blueprint for achieving durable access and commercial success

The autoimmune therapeutics landscape is at an inflection point where scientific progress, payer scrutiny, and evolving care models intersect to create both risk and opportunity. Therapeutic innovation across biologics, biosimilars, and targeted small molecules is expanding treatment options and enabling more personalized care, but these advances come with heightened operational and commercial complexity. Manufacturers that integrate clinical differentiation with resilient manufacturing, proactive payer engagement, and patient-centered delivery models will be best positioned to capture long-term value.

Regional variability in regulatory frameworks, payer priorities, and manufacturing capacity requires tailored strategies that align trial design, supply footprints, and market access tactics with local realities. The cumulative impact of tariff changes and supply chain disruptions underscores the need for strategic planning that balances cost management with uninterrupted patient access. Ultimately, success in this arena will depend on an organization's ability to translate scientific innovation into compelling value narratives supported by real-world evidence, while maintaining operational agility to adapt to policy and market shifts.

Stakeholders across R&D, commercial, regulatory, and supply chain functions must collaborate closely to convert insights into executable roadmaps that preserve access, demonstrate value to payers, and improve patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Autoimmune Disease Drugs Market, by Drug Class

  • 8.1. Biologics
    • 8.1.1. Fusion Proteins
    • 8.1.2. Monoclonal Antibodies
    • 8.1.3. Peptides
  • 8.2. Biosimilars
  • 8.3. Small Molecules

9. Autoimmune Disease Drugs Market, by Mechanism Of Action

  • 9.1. B Cell Depleting Agents
  • 9.2. Il Inhibitors
    • 9.2.1. Il17 Inhibitors
    • 9.2.2. Il23 Inhibitors
    • 9.2.3. Il6 Inhibitors
  • 9.3. Jak Inhibitors
    • 9.3.1. Jak1 Inhibitors
    • 9.3.2. Jak1/2 Inhibitors
    • 9.3.3. Jak3 Inhibitors
  • 9.4. Tnf Inhibitors

10. Autoimmune Disease Drugs Market, by Route Of Administration

  • 10.1. Oral
    • 10.1.1. Capsule
    • 10.1.2. Solution
    • 10.1.3. Tablet
  • 10.2. Parenteral
    • 10.2.1. Intravenous
    • 10.2.2. Subcutaneous

11. Autoimmune Disease Drugs Market, by Indication

  • 11.1. Inflammatory Bowel Disease
    • 11.1.1. Crohn's Disease
    • 11.1.2. Ulcerative Colitis
  • 11.2. Lupus
  • 11.3. Multiple Sclerosis
  • 11.4. Psoriasis
    • 11.4.1. Plaque Psoriasis
    • 11.4.2. Psoriatic Arthritis
  • 11.5. Rheumatoid Arthritis

12. Autoimmune Disease Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Homecare Settings
  • 12.3. Hospitals

13. Autoimmune Disease Drugs Market, by Distribution Channel

  • 13.1. Offline
  • 13.2. Online

14. Autoimmune Disease Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Autoimmune Disease Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Autoimmune Disease Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Autoimmune Disease Drugs Market

18. China Autoimmune Disease Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Amgen Inc.
  • 19.7. Astellas Pharma Inc.
  • 19.8. AstraZeneca plc
  • 19.9. Baxter International Inc.
  • 19.10. Bayer AG
  • 19.11. Biogen Inc.
  • 19.12. Bristol-Myers Squibb Company
  • 19.13. Celgene Corporation
  • 19.14. Eli Lilly and Company
  • 19.15. Gilead Sciences, Inc.
  • 19.16. GlaxoSmithKline plc
  • 19.17. Johnson & Johnson
  • 19.18. Mallinckrodt plc
  • 19.19. Merck & Co., Inc.
  • 19.20. Novartis AG
  • 19.21. Pfizer Inc.
  • 19.22. Regeneron Pharmaceuticals, Inc.
  • 19.23. Roche Holding AG
  • 19.24. Sanofi S.A.
  • 19.25. Sanofi S.A.
  • 19.26. Takeda Pharmaceutical Company Limited
  • 19.27. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOSIMILARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOSIMILARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY B CELL DEPLETING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY B CELL DEPLETING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY B CELL DEPLETING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL17 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL17 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL17 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL23 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL23 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL23 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL6 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL6 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL6 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1/2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1/2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1/2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK3 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK3 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK3 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LUPUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LUPUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LUPUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 256. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 257. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 258. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 259. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 260. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 262. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 263. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 264. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 265. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 266. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 296. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 298. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 299. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 300. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 301. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 302. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 303. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 304. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 305. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 306. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 307. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 308. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 310. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 311. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 312. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 313. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 314. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 315. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 316. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. NATO AUTOIMMUNE DISEASE D